Anamorelin Hydrochloride
Phase 3Small molecule
Anamorelin Hydrochloride is one of 49 small molecule programs targeting Physical Activity. It is currently in Phase 3.
2
Indications
5
Total Trials
2
Active Trials
48
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
449 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1SHR-A1811
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Phase 3
SSGJ-707
SSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Phase 3
Anamorelin Hydrochloride
MM.D. Anderson Cancer Center
Phase 3
Neladalkib (NVL-655)
NNuvalent Inc.
Phase 3
Remeron
OOrganon and Co
Preclinical
Aqupla
Jiangsu Simcere Pharmaceutical Co., Ltd.Preclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Treatment
GSKPreclinical
Valemetostat Tosylate
Daiichi SankyoPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Non-Small Cell Lung Cancer2 trials
Physical Activity1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Anamorelin Hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- MM.D. Anderson Cancer Center